Related Experiment Video
Updated: Jul 4, 2025

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
Published on: August 1, 2013
Lymphocytic choriomeningitis arenavirus requires cellular COPI and AP-4 complexes for efficient virion production
Owen Byford1,2, Amelia B Shaw1,2, Hiu Nam Tse1,2
1School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom.
Abstract:
Lymphocytic choriomeningitis virus (LCMV) is a bisegmented negative-sense RNA virus classified within the Arenaviridae family of the Bunyavirales order. LCMV is associated with fatal disease in immunocompromized populations, and as the prototypical arenavirus, acts as a model for the many serious human pathogens within this group. Here, we examined the dependence of LCMV multiplication on cellular trafficking components using a recombinant LCMV expressing enhanced green fluorescent protein in conjunction with a curated siRNA library. The screen revealed a requirement for subunits of both the coat protein 1 (COPI) coatomer and adapter protein 4 (AP-4) complexes. By rescuing a recombinant LCMV harboring a FLAG-tagged glycoprotein (GP-1) envelope spike (rLCMV-GP1-FLAG), we showed infection resulted in marked co-localization of individual COPI and AP-4 components with both LCMV nucleoprotein (NP) and GP-1, consistent with their involvement in viral processes. To further investigate the role of both COPI and AP-4 complexes during LCMV infection, we utilized the ARF-I inhibitor brefeldin A (BFA) that prevents complex formation. Within a single 12-h cycle of virus multiplication, BFA pre-treatment caused no significant change in LCMV-specific RNA synthesis, alongside no significant change in LCMV NP expression, as measured by BFA time-of-addition experiments. In contrast, BFA addition resulted in a significant drop in released virus titers, approaching 50-fold over the same 12-h period, rising to over 600-fold over 24 h. Taken together, these findings suggest COPI and AP-4 complexes are important host cell factors required for the formation and release of infectious LCMV.
Importance:
Arenaviruses are rodent-borne, segmented, negative-sense RNA viruses, with several members responsible for fatal human disease, with the prototypic member lymphocytic choriomeningitis virus (LCMV) being under-recognised as a pathogen capable of inflicting neurological infections with fatal outcome. A detailed understanding of how arenaviruses subvert host cell processes to complete their multiplication cycle is incomplete. Here, using a combination of gene ablation and pharmacological inhibition techniques, we showed that host cellular COPI and AP-4 complexes, with native roles in cellular vesicular transport, were required for efficient LCMV growth. We further showed these complexes acted on late stages of the multiplication cycle, post-gene expression, with a significant impact on infectious virus egress. Collectively, our findings improve the understanding of arenaviruses host-pathogen interactions and reveal critical cellular trafficking pathways required during infection.
Insights
Lymphocytic choriomoriomeningitis virus (LCMV) requires host cell COPI and AP-4 complexes for efficient replication and release. Inhibiting these complexes significantly reduces infectious LCMV production, highlighting their role in viral egress.
Area of Science:
- Virology
- Cell Biology
- Molecular Biology
Background:
- Lymphocytic choriomeningitis virus (LCMV) is a model arenavirus, a bisegmented negative-sense RNA virus.
- LCMV infection can cause fatal disease, particularly in immunocompromised individuals.
- Understanding LCMV's interaction with host cell machinery is crucial for developing antiviral strategies.
Purpose of the Study:
- To identify host cellular trafficking components essential for LCMV multiplication.
- To elucidate the role of COPI and AP-4 complexes in the LCMV life cycle.
- To investigate the impact of COPI and AP-4 inhibition on infectious virus production.
Main Methods:
- Utilized a recombinant LCMV expressing GFP and a curated siRNA library to screen for host factors.
- Employed a FLAG-tagged LCMV glycoprotein (GP-1) rescue virus to visualize viral component localization.
- Used brefeldin A (BFA), an ARF-I inhibitor, to pharmacologically inhibit COPI and AP-4 complex formation.
Main Results:
- A screen identified subunits of COPI and AP-4 complexes as necessary for LCMV multiplication.
- LCMV infection led to co-localization of COPI and AP-4 components with viral nucleoprotein (NP) and GP-1.
- BFA treatment significantly inhibited the release of infectious LCMV, with a 50-fold drop in titers within 12 hours and over 600-fold within 24 hours, without affecting RNA synthesis or NP expression.
Conclusions:
- COPI and AP-4 complexes are critical host cell factors required for efficient LCMV egress.
- These complexes play a role in late stages of the LCMV multiplication cycle, specifically post-gene expression.
- Targeting cellular trafficking pathways involving COPI and AP-4 may represent a novel therapeutic approach against LCMV and other arenaviruses.
Related Concept Videos
Retrovirus Life Cycles
Leaky Scanning
Viral Recombination

